focus -WSS

focus

author：entertainment 2025-09-27 13:04:09 - browse：837

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： A pediatrician calls for Congress to pass the child tax credit deal

WSS

HPV vaccine, cervical cancer study delivers historic results

TikTok, Instagram influencers need more rules for drug ads

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Readout LOUD podcast: How biotech is using artificial intelligence

HPV vaccine, cervical cancer study delivers historic results

How digital tools helped lower hypertension in marginalized patients

Wikipedia

focus

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

TikTok, Instagram influencers need more rules for drug ads

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

There's an unseen cost to disruptive road

At least 13 dead in Texas as scorching temps continue

Flu vaccine reformulation won't be easy, manufacturers warn

Activists slam private health insurers over coverage restrictions

Senators start work on Medicare physician payment reform

Hepatitis C has a cure — but many Americans still lack access to it

Future doctors need a strong humanities education

knowledge

TikTok, Instagram influencers need more rules for drug ads

What causes osteoarthritis? Researchers study link to brain protein

Medicare threatens to cut off funding for HCA's Mission hospital

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

FDA sets aggressive timeline for overhauling inspection procedures

CVS is on a mission to consolidate health care. Will it work?

entertainment

entertainment

leisure time

focus